10/31/2025
Last weekend, news broke that the first in a class of drugs to address the underlying cause of early disease - Leqembi- has just been conditionally approved.
This is a huge step forward in approaching diagnosis with hope, and for beginning to understand treatments, rather than disengagement.
Dr. Sivananthan had the chance to discuss this news in more detail with
Add a comment...
@